Cargando…

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease

AIM: Pridopidine, a new oral drug for treatment of patients with motor symptoms associated with Huntington's Disease (HD) is currently under development. In steady‐state conditions, pridopidine elimination is mediated primarily through renal excretion. This study evaluated single dose and stead...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rabinovich‐Guilatt, L., Siegler, K. E., Schultz, A., Halabi, A., Rembratt, A., Spiegelstein, O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Clinical Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833154/ https://www.ncbi.nlm.nih.gov/pubmed/26407011 http://dx.doi.org/10.1111/bcp.12792

Ejemplares similares

Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease
por: Rabinovich‐Guilatt, Laura, et al.
Publicado: (2017)

Pridopidine activates neuroprotective pathways impaired in Huntington Disease
por: Geva, Michal, et al.
Publicado: (2016)

The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers
por: Schneider, F., et al.
Publicado: (2021)

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease
por: Waters, Susanna, et al.
Publicado: (2018)

Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Pridopidine Reverses Phencyclidine-Induced Memory Impairment
por: Sahlholm, Kristoffer, et al.
Publicado: (2018)

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
por: Schnell, David, et al.
Publicado: (2014)

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
por: Weller, Stephen, et al.
Publicado: (2013)

Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
por: Townsend, Robert W., et al.
Publicado: (2017)

Pharmacokinetic profile of defibrotide in patients with renal impairment
por: Tocchetti, Paola, et al.
Publicado: (2016)

The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor
por: Kielbasa, William, et al.
Publicado: (2013)

Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Chen, Shujun, et al.
Publicado: (2021)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe
por: Cherniakov, Irina, et al.
Publicado: (2021)

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
por: Kletzl, Heidemarie, et al.
Publicado: (2022)

Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors
por: Nijenhuis, Cynthia M., et al.
Publicado: (2016)

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment
por: Zhao, Baiteng, et al.
Publicado: (2016)

Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [(18)F] fluspidine and [(18)F] fallypride PET study
por: Grachev, Igor D., et al.
Publicado: (2020)

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
por: Dowell, J, et al.
Publicado: (2008)

Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
por: Desai, Amit, et al.
Publicado: (2016)

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
por: Frost, Charles E., et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function
por: Shoaf, Susan E, et al.
Publicado: (2014)

Internet-delivered therapist-guided physical activity for mild to moderate depression: a randomized controlled trial
por: Ström, Morgan, et al.
Publicado: (2013)

Theory of Mind Is Impaired in Mild to Moderate Huntington’s Disease Independently from Global Cognitive Functioning
por: Lagravinese, Giovanna, et al.
Publicado: (2017)

New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment
por: Tellone, Valeria, et al.
Publicado: (2018)

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
por: Kohan, Donald E, et al.
Publicado: (2014)

Mild Cognitive Impairment as an Early Landmark in Huntington's Disease
por: Zhang, Ying, et al.
Publicado: (2021)

A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment
por: Lin, Swan, et al.
Publicado: (2022)

3244 The Autonomic Nervous System as a Potential Therapeutic Target in Huntington Disease
por: Schultz, Jordan L, et al.
Publicado: (2019)

Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose
por: Darpo, Borje, et al.
Publicado: (2023)

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment
por: Mercier, Anne-Kristina, et al.
Publicado: (2023)

Correction to: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment
por: Lin, Swan, et al.
Publicado: (2022)

Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma
por: Geva, Michal, et al.
Publicado: (2021)

Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study
por: McGarry, Andrew, et al.
Publicado: (2020)

Huntington’s Disease Clinical Trials Corner: February 2018
por: Rodrigues, Filipe B., et al.
Publicado: (2018)

Huntington’s Disease Clinical Trials Corner: August 2023
por: Estevez-Fraga, Carlos, et al.
Publicado: (2023)

Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers
por: Schneider, Frank, et al.
Publicado: (2020)

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
por: Kurata, Akifumi, et al.
Publicado: (2019)

Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect
por: Schneider, Frank, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4v239acbtctoancco0urn6109i